References:
1. Jiang M, Stanke J, Lahti JM. The connections between neural crest
development and Neuroblastoma. Curr Top Dev Biol . 2011;94:77-127.
2. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the
international criteria for Neuroblastoma diagnosis, staging, and
response to treatment. Journal of Clinical Oncology .
1993;11(8):1466-1477.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. The
Lancet . 2007/06/23/ 2007;369(9579):2106-2120.
4. Monclair T, Brodeur GM, Ambros PF, et al. The International
Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force
report. J Clin Oncol . Jan 10 2009;27(2):298-303.
5. Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear
medicine imaging in Neuroblastoma. European Journal of Nuclear
Medicine and Molecular Imaging . 2018/10/01 2018;45(11):2009-2024.
6. Geatti O, Shapiro B, Sisson JC, et al. Iodine-131
metaiodobenzylguanidine scintigraphy for the location of Neuroblastoma:
preliminary experience in ten cases. J Nucl Med . Jul
1985;26(7):736-42.
7. Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of
the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human
Neuroblastoma cells. Biochem Pharmacol . Jun 15
1990;39(12):1959-64.
8. Kroiss A, Putzer D, Uprimny C, et al. Functional imaging in
phaeochromocytoma and Neuroblastoma with 68Ga-DOTA-Tyr3-octreotide
positron emission tomography and 123I-metaiodobenzylguanidine: a
clarification. European Journal of Nuclear Medicine and Molecular
Imaging . 2012/03/01 2012;39(3):543-543.
9. Bleeker G, Tytgat GA, Adam JA, et al. 123I-MIBG scintigraphy and
18F-FDG-PET imaging for diagnosing Neuroblastoma. Cochrane
Database Syst Rev . Sep 29 2015;2015(9):Cd009263.
10. Kong G, Hofman MS, Murray WK, et al. Initial Experience With
Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide
Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.Journal of Pediatric Hematology/Oncology . 2016;38(2):87-96.
11. Gains JE, Bomanji JB, Fersht NL, et al. 177Lu-DOTATATE molecular
radiotherapy for childhood Neuroblastoma. J Nucl Med . Jul
2011;52(7):1041-7.
12. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson
JC. Neuroblastoma: positron emission tomography with
2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with
metaiodobenzylguanidine scintigraphy. Radiology . Jun
1996;199(3):743-50.
13. O’Dorisio MS, Chen F, O’Dorisio TM, Wray D, Qualman SJ.
Characterization of somatostatin receptors on human Neuroblastoma
tumors. Cell Growth Differ . Jan 1994;5(1):1-8.
14. Albers AR, O’Dorisio MS, Balster DA, et al. Somatostatin receptor
gene expression in Neuroblastoma. Regul Pept . Mar 17
2000;88(1-3):61-73.
15. Agrawal K, Kumar R, Shukla J, Bhattacharya A, Mittal BR. Ga-68
DOTATATE positron emission tomography/computer tomography in initial
staging and therapy response evaluation in a rare case of primary
Neuroblastoma in neck. Indian J Nucl Med . 2014;29(3):175-176.
16. Sullivan M, Bouffet E, Rodriguez-Galindo C, et al. TITLE: The
COVID-19 PANDEMIC: A Rapid Global response for Children with Cancer from
SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI and St Jude Global.Pediatric Blood & Cancer . 04/01 2020.
17. Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S. Review:
The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and
Treatment of Childhood Neuroblastoma. Curr Radiopharm . 2018
2018;11(1):14-21.
18. Suc A, Lumbroso J, Rubie H, et al. Metastatic Neuroblastoma in
children older than one year: Prognostic significance of the initial
metaiodobenzylguanidine scan and proposal for a scoring system.Cancer . 1996;77(4):805-811.
19. Lewington V, Lambert B, Poetschger U, et al. (123)I-mIBG
scintigraphy in Neuroblastoma: development of a SIOPEN semi-quantitative
reporting ,method by an international panel. Eur J Nucl Med Mol
Imaging . Feb 2017;44(2):234-241.
20. Van Vickle SS, Thompson RC. 123I-MIBG Imaging: Patient Preparation
and Technologist’s Role. J Nucl Med Technol . Jun 2015;43(2):82-6.
21. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in Neuroblastoma
Diagnostic Imaging and Therapy. Radiographics . Jan-Feb
2016;36(1):258-78.
22. Maurice JB, Troke R, Win Z, et al. A comparison of the performance
of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and
follow-up of phaeochromocytoma and paraganglioma. European Journal
of Nuclear Medicine and Molecular Imaging . 2012/08/01
2012;39(8):1266-1270.
23. Naji M, Zhao C, Welsh SJ, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in
identifying malignant neural crest tumours. Mol Imaging Biol . Aug
2011;13(4):769-75.
24. Bombardieri E, Giammarile F, Aktolun C, et al.
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure
guidelines for tumour imaging. Eur J Nucl Med Mol Imaging . Dec
2010;37(12):2436-46.
25. Sandström M, Velikyan I, Garske-Román U, et al. Comparative
biodistribution and radiation dosimetry of 68Ga-DOTATOC and
68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med .
Oct 2013;54(10):1755-9.
26. Jacobs F, Thierens H, Piepsz A, et al. Optimised tracer-dependent
dosage cards to obtain weight-independent effective doses.European Journal of Nuclear Medicine and Molecular Imaging .
2005/04/01 2005;32(5):581-588.
27. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured
human dosimetry of 68Ga-DOTATATE. J Nucl Med . Jun
2013;54(6):855-60.